All In MedTech

Device Trial Radar · NCT04796220

Focused Ultrasound and Gemcitabine in Breast Cancer

Focused Ultrasound With Low-Dose Gemcitabine to Augment Immune Control of Early Stage Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Jan 27, 2022

Primary completion

Sep 2029

Study completion Feb 2030

Sponsor

Lead sponsor
Patrick Dillon, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 12, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test the use of focused ultrasound ablation, low-dose gemcitabine (a chemotherapy) and the combination of focused ultrasound ablation plus low-dose gemcitabine in patients with early-stage breast cancers. We will be testing the effects of each of these regimens on cells in the immune system. We hypothesize that the combination of focused ultrasound ablation and gemcitabine will decrease myeloid-derived suppressor cells and will increase T cell activity. We also hypothesize that focused ultrasound ablation and low-dose gemcitabine will be safe and will result in non-inferior surgical completion rates and tumor margin assessments.

Conditions

  • Breast Cancer
  • Breast Neoplasms

Interventions

  • Focused UltrasoundDevice

    Focused ultrasound will be applied to up to 2 breast lesions on day 8.

  • Gemcitabine and Focused UltrasoundOther

    Gemcitabine (900 mg/m2) will be administered intravenously on day 1.Focused ultrasound will be applied to up to 2 breast lesions on day 8.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with any ≥ grade 3 adverse eventTime frame: Adverse events collected through 30 days after the last study treatment
  2. Rate of participants experiencing a delay in surgeryTime frame: Through month 7 (Follow-up visit 2)
  3. Rate of positive margins following surgeryTime frame: Day 22

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Virginia

    Charlottesville, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.